

Asthma: From Phenotypes to Personalized Medicine

Guest Editor:

Prof. Dr. Petros Bakakos

1st University Department of
Respiratory Medicine, National
and Kapodistrian University of
Athens, Athens, Greece

Deadline for manuscript
submissions:


closed (30 April 2022)

Message from the Guest Editor

Asthma is a heterogenous disease of the airways with a high prevalence worldwide and characterized by chronic inflammation. The aim of asthma management is the control of the disease, and the cornerstone of asthma treatment is inhaled corticosteroids. As asthma becomes less well-controlled and more severe (moderate-to-severe), medications are more or less effective in particular phenotypes. Phenotypes and endotypes are known, respectively, as pathologic and molecular features that might not be directly associated with each other but may define a better response to treatment, and that is important from a clinical point of view. Accordingly, it has become necessary to define the phenotype of an asthmatic patient mainly based upon biomarkers and clinical features, and this has led to treatable traits and personalized medicine. Each asthmatic, and especially severe ones, is evaluated in terms of their phenotype, followed by the initiation of a treatment regimen that would be more effective in improving symptoms and/or reducing exacerbations, both of which are considered measures of control.

Prof. Dr. Petros Bakakos
Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer
Institute, Winston-Salem, NC
27103, USA
2. Division of Hematologic
Malignancies and Cellular
Therapy, Duke University,
Durham, NC 27710, USA

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, ‘omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank: JCR - Q2 (*Medicine, General & Internal*) CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Journal of Personalized Medicine
Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/jpm
jpm@mdpi.com
[X@JPM_MDPI](https://twitter.com/JPM_MDPI)